Form 4: Context Therapeutics Director Linda West Granted Stock Options

Director Linda West of Context Therapeutics Inc. [CNTX] was granted stock options to purchase 25,000 shares of common stock on June 13, 2024.

Summary

• Linda West, a director of Context Therapeutics Inc. (CNTX), was granted stock options on June 13, 2024.
• The options allow West to purchase 25,000 shares of CNTX common stock at an exercise price of $1.97 per share.
• The options vest on the earlier of June 13, 2025, or the Issuer's 2025 annual meeting of stockholders, contingent upon continued service with the Issuer.
• The options expire on June 12, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine grant of stock options, which is neither particularly positive nor negative on its own. It's a standard practice for aligning director interests with shareholders.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options to their directors and officers.
• The size of the grant (25,000 shares) and the vesting schedule (one year or annual meeting) appear to be within typical industry ranges for a company of Context Therapeutics' size and stage.

Stakeholder Impact

• The stock option grant could have a slightly dilutive effect on existing shareholders if the options are exercised.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates